Price History
Feb 9, 2026 — May 23, 2026Investment Snapshot
- Piotroski F-Score 2/9 — signs of financial weakness
- Loss-making — negative ROE of -24.5%
Impact BioMedical, Inc. Common Stock (IBO) is a Healthcare company operating in Pharmaceutical Preparations, listed on the AMEX , with a market capitalisation of $59 million . Key value metrics: Piotroski F-Score 2 out of 9 .
Value Score
Key Metrics
Current vs 5-Year Average
Based on 3 years of SEC filingsRevenue & Net Income
Financial Statements
| Metric | FY22 | FY23 | FY24 |
|---|---|---|---|
| Revenue | $X.XB | $X.XB | $X.XB |
| Gross Profit | $X.XB | $X.XB | $X.XB |
| Operating Income | $X.XB | $X.XB | $X.XB |
| Net Income | $X.XB | $X.XB | $X.XB |
| EBITDA | $X.XB | $X.XB | $X.XB |
| Total Assets | $X.XB | $X.XB | $X.XB |
| Total Liabilities | $X.XB | $X.XB | $X.XB |
Impact BioMedical, Inc. Common Stock — Fundamental Analysis Summary
On financial health, IBO shows a weak Piotroski F-Score of 2/9, a signal of deteriorating financial health, and negative return on equity of -24.5% (sector average: -20.6%).
StockPik's composite Value Score for IBO is 25/100 — reflecting current market or financial concerns. The score is built from ten fundamental signals: P/E, P/B, PEG ratio, P/S ratio, return on equity, gross margin, debt-to-equity, current ratio, dividend yield, and Piotroski F-Score.
IBO reports a thin gross margin of -1,225.0% (sector average: 40.1%) and a negative operating margin of -16,875.0%.
IBO shows earnings growing at 52%.